GGrantIndex
← Search

CORE--MOLECULAR CYTOGENETICS FACILITY

$78,870P30FY2002CANIH

Case Western Reserve University, Cleveland OH

Investigators

Linked publications, trials & patents

Trial NCT05340673Trial NCT05198830Trial NCT02590107Trial NCT02535325Trial NCT02451124Trial NCT02419846Trial NCT02417948Trial NCT02392377Trial NCT02388932Trial NCT02383433Trial NCT02375477Trial NCT02354326Trial NCT02345460Trial NCT02342730Trial NCT02337465Trial NCT02327390Trial NCT02319889Trial NCT02307474Trial NCT02287636Trial NCT02252393Trial NCT02181478Trial NCT02179762Trial NCT02163317Trial NCT02158767Trial NCT02153450Trial NCT02135562Trial NCT02131207Trial NCT02129582Trial NCT02129569Trial NCT02129517Trial NCT02129218Trial NCT02128373Trial NCT02108587Trial NCT02100423Trial NCT02084147Trial NCT02082405Trial NCT02081794Trial NCT02079155Trial NCT02073097Trial NCT02073045Trial NCT02071901Trial NCT02070458Trial NCT02070419Trial NCT02055586Trial NCT02037048Trial NCT01973062Trial NCT01959490Trial NCT01959477Trial NCT01954784Trial NCT01954732Trial NCT01951885Trial NCT01939028Trial NCT01928485Trial NCT01894061Trial NCT01408043Trial NCT00991991Trial NCT00970684Trial NCT00961220Trial NCT00956475Trial NCT00952939Trial NCT00949247Trial NCT00945061Trial NCT00941720Trial NCT00941070Trial NCT00939510Trial NCT00918892Trial NCT00918788Trial NCT00918658Trial NCT00918216Trial NCT00910039Trial NCT00909662Trial NCT00908739Trial NCT00908141Trial NCT00907699Trial NCT00905086Trial NCT00900133Trial NCT00899158Trial NCT00899132Trial NCT00898573Trial NCT00898274Trial NCT00897143Trial NCT00892385Trial NCT00873600Trial NCT00873002Trial NCT00866320Trial NCT00856115Trial NCT00853021Trial NCT00842452Trial NCT00809185Trial NCT00796978Trial NCT00795678Trial NCT00769951Trial NCT00769249Trial NCT00752323Trial NCT00740961Trial NCT00736216Trial NCT00735514Trial NCT00733252Trial NCT00732745Trial NCT00732173

Abstract

DESCRIPTION (provided by applicant): The Molecular Cytogenetics Core Facility provides Cancer Center investigators cytogenetic and molecular DNA analysis of fresh cells and tissue, established and somatic cell lines, human tumors and mouse tumors, particularly those from transgenic mice. This Core is new since the last submission of this Cancer Center Grant and was developed at the request of members of Programs 1, 3, 5 and 6. Cytogenetic services consist of routine Giemsa (G)-banding and C-banding on fibroblast, lymphoblast or somatic cell hybrid lines for the purpose of determining karyotypes. The service also includes utilization of fluorescence in situ hybridization (FISH) for better clarification of these karyotypes, including both m-FISH (multicolor FISH) and SKY (spectral karyotyping), that uses 24 different colors to analyze chromosomal changes. FISH is also utilized to study chromosomal changes in interphase cells in tumors (especially in paraffin sections), in bone marrow transplants, and for chromosomal localization of genes. The molecular service of this Core consists of microsatellite analysis of tumors for loss of heterozygosity, mutation analysis of tumors, and chimerism studies of bone marrow transplants. In some instances to perform the services, tissue culture services are needed and include: general growth, maintenance, and freezing of patients? cell lines; transformation of lymphocytes to generate permanent lymphoblast lines; preparation of DNA from cell lines and peripheral blood; and generation of somatic cell lines as needed. In other instances, to perform the services, new, specialized services including comparative genomic hybridization (CGH) and chimerism analysis have been developed. These analyses have been facilitated by the addition of two computer-assisted microscopy units and a DNA sequencer. In response to user requests, the facility actively develops new technology in molecular cytogenetics.

View original record on NIH RePORTER →